In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)

Paper commented by the ESC WG on Cellular Biology of the Heart

Atherosclerosis, Cerebrovascular Diseases, Aneurysm, Restenosis


Lipoprotein(a) [Lp(a)] is a cholesterol-rich particle composed of a molecule of apolipoprotein B100 linked to a molecule of apolipoprotein(a). Lp(a) has been shown as crucial mediator of atherosclerosis and valvular calcification in the recent years and has only recently been subject of promising novel lipid-lowering agents. In this study, patients with cardiovascular diseases (CVD) received Lp(a) lowering agents including oligonucleotide therapy or PCSK9 antibody treatment. Antisense-treatment lowered Lp(a) levels to a much higher extent (47%) than PCSK9 antibody treatment (16%). In parallel, antisense-treatment reduced inflammatory gene expression and transendothelial migration in monocytes of CVD patients. However, PCSK9 administration did not change transcriptome nor migration properties of monocytes.  Altogether, Lp(a) emerges as promising target for the reduction of atherosclerosis and cardiovascular disease. Both PCSK9 antibody and apolipoprotein(a) antisense treatment show encouraging results for this purpose. 

References


Stiekema LCA et al. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). Eur Heart J. 2020.

 

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.